[Special Stock] Korea Pharma Expects Fenofibrate for Those Having Difficulty Receiving COVID-19 Vaccination

[Asia Economy Reporter Hyunseok Yoo] Korea Pharma is showing strong performance. The expectation that Phenocorin capsules, produced in-house by Korea Pharma, have efficacy in inhibiting COVID-19 virus infection appears to be influencing the stock price.

As of 9:21 AM on the 18th, Korea Pharma was trading at 71,200 KRW, up 22.34% (13,000 KRW) compared to the previous trading day.

Korea Pharma announced that a paper by a joint research team from the University of Birmingham and Keele University in the UK, the San Raffaele Scientific Institute in Italy, and the University of Copenhagen in Denmark was published in the latest issue of the international pharmacology journal Frontiers in Pharmacology. The joint research team screened FDA-approved drugs for those with inhibitory effects on COVID-19 virus infection and discovered the efficacy of fenofibrate.

According to the study, fenofibrate and its active form fenofibric acid reduced COVID-19 virus infection by up to 70% in in vitro experiments. The research team urged the initiation of clinical trials involving COVID-19 patients.

If clinical results prove the sufficient efficacy of fenofibrate, it is expected to serve as an effective vaccine alternative for groups who have difficulty receiving vaccines, including countries struggling to secure vaccines, children, immunodeficient patients, and patients receiving immunosuppressants.

Korea Pharma holds ’Phenocorin,‘ which is fenofibric acid, the active form of the dyslipidemia treatment fenofibrate, combined with choline salt. This formulation increases hydrophilicity to improve absorption and allows administration regardless of meals. Phenocorin is a capsule formulation containing mini tablets identical to the original domestic formulation and is produced in-house by Korea Pharma.

This content was produced with the assistance of AI translation services.